Universe Pharmaceuticals INC (UPC) — SEC Filings

Overview

Universe Pharmaceuticals INC (UPC) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Sep 3, 2025: Universe Pharmaceuticals INC held its reconvened 2025 Annual General Meeting of Shareholders on September 2, 2025, in Ji'an, Jiangxi, China. The meeting, originally scheduled for August 26, 2025, addressed company business. The company is incorporated in F4 and has a fiscal year end of September 30.

Sentiment Summary

Across 24 filings, the sentiment breakdown is: 4 bearish, 19 neutral, 1 mixed. The dominant filing sentiment for Universe Pharmaceuticals INC is neutral.

Filing Type Overview

Universe Pharmaceuticals INC (UPC) has filed 22 6-K, 2 20-F with the SEC between Jan 2024 to Sep 2025.

Filings by Year

2025 · 2024

Recent Filings (24)

• Universe Pharmaceuticals INC Holds 2025 Annual Shareholder Meeting — 6-K · Sep 3, 2025 Risk: low
  Universe Pharmaceuticals INC held its reconvened 2025 Annual General Meeting of Shareholders on September 2, 2025, in Ji'an, Jiangxi, China. The meeting, origin
• Universe Pharmaceuticals Meeting Adjourned Due to Lack of Quorum — 6-K · Aug 26, 2025 Risk: low
  Universe Pharmaceuticals INC convened its 2025 annual general meeting on August 26, 2025, but it was adjourned due to a lack of quorum. The meeting has been res
• Universe Pharmaceuticals Schedules 2025 Shareholder Meeting — 6-K · Jul 29, 2025 Risk: low
  Universe Pharmaceuticals INC is holding its 2025 Annual General Meeting of Shareholders on July 29, 2025. The company has furnished a Notice and Proxy Statement
• Universe Pharmaceuticals Reports Q1/Q2 Revenue Drop — 6-K · Jul 3, 2025 Risk: medium
  Universe Pharmaceuticals INC reported financial results for the six months ended March 31, 2025. Revenues decreased by 29.0% to $9.2 million compared to $12.9 m
• Universe Pharmaceuticals Files 2024 Annual Report — 20-F · Apr 29, 2025 Risk: medium
  Universe Pharmaceuticals Inc. filed its annual report on Form 20-F for the fiscal year ended September 30, 2024. The company, incorporated in F4 and headquarter
• Universe Pharmaceuticals Announces Share Consolidation — 6-K · Mar 20, 2025 Risk: low
  Universe Pharmaceuticals INC announced a share consolidation, effective March 20, 2025. This move aims to adjust the number of outstanding ordinary shares, with
• Universe Pharmaceuticals INC Holds Shareholder Meeting — 6-K · Mar 11, 2025 Risk: low
  Universe Pharmaceuticals INC held an extraordinary general meeting of shareholders on March 8, 2025, which was a re-convening of a meeting originally scheduled
• Universe Pharmaceuticals Adjourns Shareholder Meeting — 6-K · Mar 3, 2025 Risk: medium
  Universe Pharmaceuticals INC convened an extraordinary general meeting of shareholders on March 1, 2025. Due to a lack of quorum, the meeting was adjourned to M
• Universe Pharmaceuticals Gets Nasdaq Delisting Warning — 6-K · Feb 25, 2025 Risk: high
  Universe Pharmaceuticals INC filed a Form 6-K on February 25, 2025, reporting a staff determination notice from Nasdaq concerning its delayed annual report. The
• Universe Pharmaceuticals INC Holds Shareholder Meeting — 6-K · Feb 20, 2025 Risk: low
  Universe Pharmaceuticals INC held an extraordinary general meeting of shareholders on February 19, 2025, which was a re-convening of a meeting originally schedu
• Universe Pharmaceuticals Adjourns Shareholder Meeting Due to Lack of Quorum — 6-K · Feb 18, 2025 Risk: medium
  Universe Pharmaceuticals INC convened an extraordinary general meeting of shareholders on February 17, 2025. Due to a lack of quorum, the meeting was adjourned
• Universe Pharmaceuticals Files 6-K Report — 6-K · Feb 11, 2025 Risk: low
  Universe Pharmaceuticals INC, incorporated in the Cayman Islands, filed a Form 6-K on February 11, 2025. The filing is a report of a foreign private issuer for
• Universe Pharmaceuticals Receives Nasdaq Delisting Notice — 6-K · Feb 3, 2025 Risk: high
  Universe Pharmaceuticals INC received a Nasdaq delisting notice on February 3, 2025, indicating potential delisting from the Nasdaq Capital Market. The company
• Universe Pharmaceuticals Schedules Shareholder Meeting for Jan 2025 — 6-K · Jan 30, 2025 Risk: low
  Universe Pharmaceuticals INC announced an Extraordinary General Meeting of Shareholders to be held in January 2025. The meeting will discuss and vote on propose
• Universe Pharmaceuticals Sells 388,000 Shares — 6-K · Dec 12, 2024 Risk: medium
  On December 6, 2024, Universe Pharmaceuticals INC entered into a Securities Purchase Agreement to issue and sell 388,000 ordinary shares. The company is a Cayma
• Universe Pharmaceuticals Announces Share Consolidation — 6-K · Nov 13, 2024 Risk: medium
  Universe Pharmaceuticals INC announced a share consolidation, effective November 13, 2024. This move aims to adjust the number of outstanding ordinary shares to
• Universe Pharmaceuticals Gets Nasdaq Bid Price Warning — 6-K · Nov 1, 2024 Risk: medium
  Universe Pharmaceuticals INC received a notification from Nasdaq on November 1, 2024, indicating a deficiency in meeting the minimum bid price requirement. The
• Universe Pharmaceuticals Appoints New Auditor — 6-K · Oct 10, 2024 Risk: low
  Universe Pharmaceuticals INC (Nasdaq: UPC) announced on October 8, 2024, the appointment of Enrome LLP as its new independent registered public accounting firm.
• Universe Pharmaceuticals Holds 2024 Annual Meeting, Approves Proposals — 6-K · Sep 27, 2024 Risk: low
  Universe Pharmaceuticals INC held its 2024 Annual General Meeting on September 27, 2024, where shareholders approved all nine proposals presented. The meeting t
• Universe Pharmaceuticals Files 6-K Report — 6-K · Sep 20, 2024 Risk: low
  Universe Pharmaceuticals INC filed a Form 6-K on September 20, 2024, reporting for the period ending March 31, 2024. The filing is a report of a foreign private
• Universe Pharmaceuticals Files 6-K for August 2024 AGM — 6-K · Sep 3, 2024 Risk: low
  Universe Pharmaceuticals INC filed a Form 6-K on September 3, 2024, for the month of August 2024. The filing is related to the company's 2024 Annual General Mee
• Universe Pharmaceuticals Closes Public Offering — 6-K · Jul 18, 2024 Risk: medium
  Universe Pharmaceuticals INC announced the closing of its self-underwritten public offering on July 15, 2024. The company sold 20,000,000 ordinary shares at a p
• Universe Pharma Transfers to Nasdaq Capital Market, Avoids Delisting — 6-K · Feb 7, 2024
  Universe Pharmaceuticals INC, a Chinese pharmaceutical company, successfully transferred its ordinary shares from the Nasdaq Global Market to the Nasdaq Capital
• Universe Pharmaceuticals INC Files Annual Report on Form 20-F — 20-F · Jan 30, 2024 Risk: low
  Universe Pharmaceuticals INC (UPC) filed a Foreign Annual Report (20-F) with the SEC on January 30, 2024. Universe Pharmaceuticals INC filed its annual report o

Risk Profile

Risk Assessment: Of UPC's 23 recent filings, 2 were flagged as high-risk, 8 as medium-risk, and 13 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Key Executives

• Gang Lai

Industry Context

Universe Pharmaceuticals INC operates within the pharmaceutical preparations industry.

Top Tags

corporate-governance (10) · shareholder-meeting (9) · foreign-private-issuer (4) · pharmaceuticals (3) · filing-update (2) · share-consolidation (2) · adjournment (2) · sec-filing (2) · compliance (2) · nasdaq (2)

Key Numbers

• Revenues (Six Months Ended March 31, 2025): $9.2M — Represents a 29% decrease from the prior year period.
• Loss from Operations (Six Months Ended March 31, 2025): $2.3M — Increased by 33.7% compared to the prior year period.
• Net Loss (Six Months Ended March 31, 2025): $3.3M — Indicates a worsening financial performance.
• Fiscal Year End: 20240930 — The period covered by the annual report.
• Filing Date: 20250429 — The date the 20-F was submitted to the SEC.
• Ordinary Shares: 388,000 — Number of shares Universe Pharmaceuticals INC agreed to issue and sell in a registered direct offering.
• Proposals Approved: 9 — Shareholders unanimously approved all nine proposals at the annual general meeting.
• SEC File Number: 001-40231 — Identifies the company's filing history with the SEC
• Ordinary Shares Sold: 20,000,000 — Represents the volume of the public offering.
• Price Per Share: $1.25 — The price at which each ordinary share was offered.
• Ordinary Shares Outstanding: 3,645,974 — As of September 30, 2023
• Par Value per Ordinary Share: 0.01875 — As of September 30, 2023

Related Companies

UNVP · URPH

Frequently Asked Questions